Trial Profile
A Randomized, Double-blind, Multi-center, Placebo-controlled, Cross-over Study to Determine the Consistency of Response for Trexima (Sumatriptan 85mg/Naproxen Sodium 500mg) Administered During the Mild Pain Phase for the Acute Treatment of Multiple Migraine Attacks
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Naproxen sodium/sumatriptan (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK